COX10 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q12887 |
---|---|
Clone Names | 90921008 |
Gene ID | 1352 |
---|---|
Other Names | Protoheme IX farnesyltransferase, mitochondrial, 251-, Heme O synthase, COX10 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | COX10 |
---|---|
Function | Converts protoheme IX and farnesyl diphosphate to heme O. |
Cellular Location | Mitochondrion membrane; Multi-pass membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cytochrome c oxidase (COX), the terminal component of themitochondrial respiratory chain, catalyzes the electron transferfrom reduced cytochrome c to oxygen. This component is aheteromeric complex consisting of 3 catalytic subunits encoded bymitochondrial genes and multiple structural subunits encoded bynuclear genes. The mitochondrially-encoded subunits function inelectron transfer, and the nuclear-encoded subunits may function inthe regulation and assembly of the complex. This nuclear geneencodes heme A:farnesyltransferase, which is not a structuralsubunit but required for the expression of functional COX andfunctions in the maturation of the heme A prosthetic group of COX.This protein is predicted to contain 7-9 transmembrane domainslocalized in the mitochondrial inner membrane. A gene mutation,which results in the substitution of a lysine for an asparagine(N204K), is identified to be responsible for cytochrome c oxidasedeficiency. In addition, this gene is disrupted in patients withCMT1A (Charcot-Marie-Tooth type 1A) duplication and with HNPP(hereditary neuropathy with liability to pressure palsies)deletion.
References
Chen, Z., et al. Oncogene 29(30):4362-4368(2010)Vitali, M., et al. J Neural Transm 116(12):1635-1641(2009)Dassa, E.P., et al. EMBO Mol Med 1(1):30-36(2009)Veluthakal, R., et al. Diabetes 56(1):204-210(2007)Coenen, M.J., et al. Ann. Neurol. 56(4):560-564(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.